Please try another search
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Anatoly Dritschilo | 80 | 2012 | Co-Founder, CEO & Chairman of the Board |
Theodore L. Phillips | 91 | 2013 | Chairman of Scientific Advisory Committee |
Milton Brown | 59 | 2012 | Co-Founder & Director |
Christopher H. Senanayake | 66 | 2021 | Independent Director |
J. Martin Brown | - | 2017 | Member of Scientific Advisory Committee |
Steven Richards | 55 | 2012 | Independent Director |
Bette Jacobs | 72 | 2022 | Independent Director |
Joseph Armstrong | - | 2021 | Member of Scientific Advisory Committee |
Alejandro Villagra | - | 2017 | Member of Scientific Advisory Committee |
Joshua M. Schafer | 52 | 2019 | Independent Director |
Ralph R. Weichselbaum | - | 2013 | Member of Scientific Advisory Committee |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review